Amantadine's role in the treatment of levodopa-induced dyskinesia.
作者信息
Rodnitzky Robert L, Narayanan Nandakumar S
机构信息
From the Department of Neurology (R.L.R., N.S.N.), and Aging, Mind, and Brain Initiative (N.S.N.), University of Iowa College of Medicine, Iowa City.
出版信息
Neurology. 2014 Jan 28;82(4):288-9. doi: 10.1212/WNL.0000000000000068. Epub 2013 Dec 26.
Abstract
摘要
相似文献
1
Amantadine's role in the treatment of levodopa-induced dyskinesia.
Neurology. 2014 Jan 28;82(4):288-9. doi: 10.1212/WNL.0000000000000068. Epub 2013 Dec 26.
2
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):198-200.
3
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Mov Disord. 2004 Oct;19(10):1256-8. doi: 10.1002/mds.20194.
4
The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Clin Neuropharmacol. 2000 Mar-Apr;23(2):82-5. doi: 10.1097/00002826-200003000-00004.
5
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Arch Neurol. 1999 Nov;56(11):1383-6. doi: 10.1001/archneur.56.11.1383.
6
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Neurodegener Dis Manag. 2018 Apr;8(2):73-80. doi: 10.2217/nmt-2018-0001. Epub 2018 Mar 22.
7
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Drugs. 2019 Sep;79(13):1367-1374. doi: 10.1007/s40265-019-01170-5.
8
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.
9
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Mov Disord. 2015 May;30(6):788-95. doi: 10.1002/mds.26159. Epub 2015 Feb 4.
10
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Brain Nerve. 2022 May;74(5):468-473. doi: 10.11477/mf.1416202066.
引用本文的文献
1
Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine.
Exp Neurol. 2023 Nov;369:114522. doi: 10.1016/j.expneurol.2023.114522. Epub 2023 Aug 26.
2
The Lisbon Supramolecular Green Story: Mechanochemistry towards New Forms of Pharmaceuticals.
Molecules. 2020 Jun 11;25(11):2705. doi: 10.3390/molecules25112705.
3
Update on the Management of Parkinson's Disease for General Neurologists.
Parkinsons Dis. 2020 Mar 26;2020:9131474. doi: 10.1155/2020/9131474. eCollection 2020.
4
Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases.
Int J Mol Sci. 2017 Oct 12;18(10):2128. doi: 10.3390/ijms18102128.
5
New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.
Front Biol (Beijing). 2015 Jun;10(3):230-238. doi: 10.1007/s11515-015-1360-4. Epub 2015 May 13.
6
Approved Antiviral Drugs over the Past 50 Years.
Clin Microbiol Rev. 2016 Jul;29(3):695-747. doi: 10.1128/CMR.00102-15.
7
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.
Neurobiol Dis. 2016 Jul;91:47-58. doi: 10.1016/j.nbd.2016.02.019. Epub 2016 Feb 24.
8
Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.
P T. 2015 Nov;40(11):747-73.
9
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Mov Disord. 2015 Dec;30(14):1901-1911. doi: 10.1002/mds.26453. Epub 2015 Nov 17.
10
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
PLoS One. 2015 Aug 31;10(8):e0135949. doi: 10.1371/journal.pone.0135949. eCollection 2015.
本文引用的文献
1
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050. Epub 2013 Dec 26.
2
Which dyskinesia scale best detects treatment response?
Mov Disord. 2013 Mar;28(3):341-6. doi: 10.1002/mds.25321. Epub 2013 Feb 6.
3
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
Mov Disord. 2011 Oct;26 Suppl 3:S2-41. doi: 10.1002/mds.23829.
4
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.
J Neural Transm (Vienna). 2011 Dec;118(12):1661-90. doi: 10.1007/s00702-011-0698-2. Epub 2011 Sep 1.
5
Molecular mechanisms of L-DOPA-induced dyskinesia.
Nat Rev Neurosci. 2008 Sep;9(9):665-77. doi: 10.1038/nrn2471.
6
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
Mov Disord. 2005 Feb;20(2):190-9. doi: 10.1002/mds.20324.
7
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Ann Neurol. 2005 Jan;57(1):17-26. doi: 10.1002/ana.20296.
8
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141-3.
Zotero 插件